NCT04004663View on ClinicalTrials.gov

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

October 11, 2019

Study Completion Date

October 11, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

PF-06651600

PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04004663 - Bioavailability Study of PF-06651600 Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter